The finder
Pick what you want to change. See who actually measured it.
Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.
82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.
Or start from the compounds
Somebody handed you a stack. What is actually known about it?
Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.
Lasting longer, stamina
Does it improve endurance or work capacity?
Trials that measured how long or how hard someone could work, rather than how they looked afterwards.
94 people · 14 human studies · 11 compounds
- 30 people2 studies1 found nothing
30 adults randomized to endurance exercise, resistance exercise or control: circulating humanin rose significantly after acute endurance exercise but not resistance exercise; MOTS-c showed only a non-significant trend upward, and neither peptide correlated with fitness (VO2max, strength or muscle mtDNA copy number).
Journal of Applied Physiology, 2021 · 30 people
found nothing30 sedentary controls versus 75 professional athletes: professional athletes had lower serum MOTS-c and higher humanin than sedentary controls; MOTS-c did not differ between high- and low/moderate-endurance athletes.
Reviews in Cardiovascular Medicine, 2022 · no headcount in the line
- 30 people2 studies
30 adults randomized to endurance exercise, resistance exercise or control: circulating humanin rose significantly after a single bout of endurance exercise but not resistance exercise, and did not correlate with fitness (VO2max, strength or muscle mtDNA copy number).
Journal of Applied Physiology, 2021 · 30 people
30 sedentary controls versus 75 professional athletes: professional athletes had higher serum humanin than sedentary controls, but within the athlete group, high-endurance athletes had lower humanin than low/moderate-endurance athletes of the same age and sex.
Reviews in Cardiovascular Medicine, 2022 · no headcount in the line
- 23 people1 study1 found nothing
found nothing23 untrained men randomised to 20 mg a day of PQQ or placebo alongside a supervised six-week endurance training programme. There were no significant differences between groups in aerobic performance after endurance training (p > 0.05). Peak oxygen uptake and total test duration improved in both groups, from the...
Journal of the American College of Nutrition, 2020 · 23 people
- 11 people1 study1 found nothing
found nothingThe first randomised controlled trial. 11 healthy men aged 18 to 40, two 2-week cycles of oral clenbuterol at 80 micrograms a day versus placebo with a 3-week washout. Lean mass +0.91 kg (95% CI 0.02 to 1.81, p < 0.05), no effect on fat mass, maximal oxygen uptake -7% (p < 0.001), exercise capacity -4% (p < 0.001), no...
The Journal of Physiology, 2025 · 11 people
- no headcount stated2 studies1 found nothing
found nothing4 months of urolithin A improved muscle endurance and plasma biomarkers, though 6-minute walk and peak ATP did not differ from placebo.
JAMA Network Open, 2022 · no headcount in the line
About 12% gain in muscle strength and improved VO2 peak and 6-minute walk, though the primary peak-power endpoint was not met.
Cell Reports Medicine, 2022 · no headcount in the line
- no headcount stated1 study
The same Kiev cohort at 15 years: 39 coronary patients given 6 courses of Epithalamin over 3 years plus basic therapy versus 40 on basic therapy alone, reporting slower cardiovascular aging, preserved physical endurance, normalized melatonin rhythm and significantly lower mortality. The title says pituitary; the text...
Bulletin of Experimental Biology and Medicine, 2011 · no headcount in the line
- no headcount stated1 study
Small open study: inhaled VIP improved hemodynamics and exercise capacity in primary pulmonary hypertension patients deficient in VIP.
Journal of Clinical Investigation, 2003 · no headcount in the line
- no headcount stated1 study
Randomised crossover, 9 trained male cyclists, 0.35 g/kg racemic 1,3-butanediol or placebo before and during 85 minutes of steady exercise then a time trial. Blood D-beta-hydroxybutyrate 0.44 to 0.79 mmol/L during exercise (placebo 0.11 to 0.16), peak 1.38 mmol/L after. Moderate to severe gastrointestinal symptoms in...
International Journal of Sport Nutrition and Exercise Metabolism, 2019 · no headcount in the line
- no headcount stated1 study
30 participants, sponsor AgelessRx (a telehealth prescriber), active not recruiting. Arms combine rapamycin 2 to 6 mg weekly, metformin 500 mg daily, low-dose naltrexone, intranasal NAD+, topical glutathione and a proprietary supplement; primary endpoints VO2 max, a cognitive composite and an inflammation index....
ClinicalTrials.gov, 2025 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingRandomised 2:1, 30 overweight or obese adults aged 45 and over, MIB-626 two 500 mg tablets twice daily for 28 days. Body weight fell 1.9 kg (95 percent CI -3.3 to -0.5, P=.008), diastolic blood pressure fell 7.01 mmHg (-13.44 to -0.59, P=.034), total cholesterol fell 26.89 mg/dL (P=.004) and LDL fell 18.73 mg/dL...
Journal of Clinical Endocrinology and Metabolism, 2023 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingIncluded as the contrast, and it is not urolithin B. This is a randomised trial of urolithin A in older adults, in which muscle endurance and plasma biomarkers improved while the six-minute walk and peak ATP did not differ from placebo. Urolithin B has no trial of this kind, or of any kind.
JAMA Network Open, 2022 · no headcount in the line
- no headcount stated0 studies
SLU-PP-332 triggered an aerobic-exercise-like transcriptional program in muscle and increased running endurance in mice.
ACS Chemical Biology, 2023 · no headcount in the line
- no headcount stated0 studies
GW501516 plus training improved endurance in mice.
Cell, 2008 · no headcount in the line
- no headcount stated0 studies
Balb/c mice, treadmill trained for 4 weeks with AICAR and GW0742. AICAR alone potentiated endurance; the combination increased running time by 138 to 179 percent relative to exercised groups and 355 percent relative to non-exercised groups, with a fuel shift toward fat, glycogen sparing and upregulation of Pgc1a,...
Physiological Reports, 2016 · no headcount in the line
- no headcount stated0 studies
SLU-PP-332 is a synthetic pan agonist at all three estrogen-related receptors with highest potency at ERR alpha. It increased mitochondrial function and cellular respiration in a skeletal muscle cell line, and in mice increased type IIa oxidative skeletal muscle fibres, enhanced exercise endurance and induced an ERR...
ACS Chemical Biology, 2023 · no headcount in the line
- no headcount stated0 studies
Lys-Glu from month 6 of life increased physical activity and endurance, prolonged lifespan and reduced spontaneous tumors in female CBA mice.
Bulletin of Experimental Biology and Medicine, 2000 · no headcount in the line
- no headcount stated0 studies
AICAR raised endurance in untrained mice by about 44%.
Cell, 2008 · no headcount in the line
- no headcount stated0 studies
Each drug alone, started at 4 or 16 months, improved rotarod and endurance and reduced cardiac hypertrophy in aged UM-HET3 mice of both sexes; acarbose changed the cardiac lipidome more than rapamycin; some benefits male-only. Healthspan measures for the single drugs, not the combination.
Journals of Gerontology Series A, 2023 · no headcount in the line
- no headcount stated0 studies
The strongest evidence for the CD38 strategy, and it was not generated with apigenin. 78c, a highly potent and specific thiazoloquinazolinone CD38 inhibitor, reversed age-related NAD decline and improved glucose tolerance, muscle function, exercise capacity and cardiac function in mouse models of natural and...
Cell Metabolism, 2018 · no headcount in the line
- no headcount stated0 studies
Mouse. uPAR-positive senescent cells accumulate with age and were targetable with senolytic CAR T cells. A single administration improved exercise capacity in physiologically ageing mice and ameliorated metabolic dysfunction, including glucose tolerance, in aged and high-fat-diet mice, with long-lasting therapeutic...
Nature Aging, 2024 · no headcount in the line
- no headcount stated0 studies
found nothingHuman FNDC5 has an ATA rather than ATG start codon; a human construct with ATA produced about 1 percent of full-length protein. FNDC5 mRNA in human muscle biopsies from two exercise studies was unchanged by endurance or strength training, and recombinant FNDC5 or irisin did not brown human preadipocytes where BMP7...
PLoS One, 2013 · no headcount in the line
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
How this is counted
Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.
A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.
People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.
Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.
Nothing here is advice, and nothing here is a recommendation to take anything.